Tom Davis, MD @ThomasADavisMD of @GenoceaBio answers the advancing part B of GEN-009 phase 1/2a trial with first patient dosed with initial clinical results: a possible impact on broader therapy.

Continuing challenges in the area of cancer immunotherapy and vaccination, particularly the current unmet need to produce treatments that translate into meaningful results for patients. The significance on the clinical progress Genocea has made to persevere and resolve the almost insurmountable roadblocks faced by other companies while making unparalleled progress.